COVID-19 in hematopoietic cell transplant recipients.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
06
06
2020
accepted:
01
10
2020
revised:
22
09
2020
pubmed:
29
10
2020
medline:
27
4
2021
entrez:
28
10
2020
Statut:
ppublish
Résumé
In this study, we aim to report the outcome of COVID-19 in hematopoietic cell transplant (HCT) recipients. HCT recipients (n = 32) with hematological disease and hospitalized for COVID-19 were included in the study. A cohort of age and comorbid disease-matched hospitalized COVID-19 patients with hematological malignancy but not underwent HCT (n = 465), and another cohort of age and comorbid disease-matched hospitalized COVID-19 patients without cancer (n = 497) were also included in the study for comparison. Case fatality rate (CFR) was 5.6% in patients without cancer, 11.8 in patients with hematological malignancy and 15.6% in HCT recipients. The CFR in HCT recipients who were not receiving immunosuppressive agents at the time of COVID-19 diagnosis was 11.5%, whereas it was 33% in HCT recipients who were receiving an immunosuppressive agent at the time of COVID-19 diagnosis. In conclusion, our study reveals that for the current pandemic, HCT recipients, especially those receiving immunosuppressive drugs, constitute a special population of cancer patients.
Identifiants
pubmed: 33110186
doi: 10.1038/s41409-020-01084-x
pii: 10.1038/s41409-020-01084-x
doi:
Substances chimiques
Immunosuppressive Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
952-955Références
Yigenoglu TN, Ata N, Altuntas F, Bascı S, Dal MS, Korkmaz S, et al. The outcome of COVID-19 in patients with hematological malignancy. J Med Virol. 2020. https://doi.org/10.1002/jmv.26404 .
Başcı S, Ata N, Altuntaş F, Yiğenoğlu TN, Dal MS, Korkmaz S, et al. Turkish Ministry of Health, Hematology Scientific Working Group. Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors. J Oncol Pharm Pract. 20201078155220953198. https://doi.org/10.1177/1078155220953198.
World Health Organization Press Conference. The World Health Organization (WHO) Has Officially Named the Disease Caused by the Novel Coronavirus as COVID-19. https://www.who.int/emergencies/diseases/novel-coronavirus-2019 . Accessed 30 May 2020.
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl J Med 2020;382:1708–20. https://doi.org/10.1056/NEJMoa2002032 .
doi: 10.1056/NEJMoa2002032
pubmed: 32109013
Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21:335–7. https://doi.org/10.1016/S1470-2045(20)30096-6 .
doi: 10.1016/S1470-2045(20)30096-6
pubmed: 32066541
pmcid: 7159000
Huang J, Lin H, Wu Y, Fang Y, Kumar R, Chen G, et al. COVID-19 in posttransplant patients-report of 2 cases. Am J Transplant. 2020. https://doi.org/10.1111/ajt.15896 .
Haroon A, Alnassani M, Aljurf M, Ahmed SO, Shaheen M, Hanbli A, et al. COVID‐19 post hematopoietic cell transplant, a report of 11 cases from a single center. Mediterr J Hematol Infect Dis. 2020;12:e2020070. https://doi.org/10.4084/MJHID.2020.070 .
doi: 10.4084/MJHID.2020.070
pubmed: 32952981
pmcid: 7485476
Vicent MG, Martinez AP, Trabazo Del Castillo M, Molina B, Sisini L, Morón-Cazalilla G, et al. COVID-19 in pediatric hematopoietic stem cell transplantation: The experience of Spanish Group of Transplant (GETMON/GETH). Pediatr Blood Cancer. 2020:e28514. https://doi.org/10.1002/pbc.28514 . [Epub ahead of print].
Malard F, Genthon A, Brissot E, Wyngaert Z, Marjanovic Z, Ikhlef S, et al. COVID-19 outcomes in patients with hematologic disease. Bone Marrow Transplant J. https://doi.org/10.1038/s41409-020-0931-4.
EBMT. COVID-19 and BMT. 2020. https://www.ebmt.org/covid-19-and-bmt . Accessed 28 May 2020.